| Identification | Back Directory | [Name]
GSK-F1 | [CAS]
1402345-92-9 | [Synonyms]
GSK-F1
CS-2666
rac-GSK-F1
PI4KA inhibitor-F1
5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamide
3-Pyridinesulfonamide, 5-[2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy- | [Molecular Formula]
C27H18F5N5O4S | [MOL File]
1402345-92-9.mol | [Molecular Weight]
603.52 |
| Chemical Properties | Back Directory | [Boiling point ]
744.3±70.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, sealed storage, away from moisture and light | [solubility ]
DMSO : 125 mg/mL (207.12 mM; Need ultrasonic) | [form ]
Solid | [pka]
5.66±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1]. | [IC 50]
PI4KA: 8.0 (pIC50); PI3KD: 6.4 (pIC50); PI4KB: 5.9 (pIC50); PI3KB: 5.9 (pIC50); PI3KG: 5.9 (pIC50); PI3KA: 5.8 (pIC50) | [storage]
Store at -20°C, sealed storage, away from moisture and light | [References]
[1] Bojjireddy N, et al. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem. 2014 Feb 28;289(9):6120-32. DOI:10.1074/jbc.M113.531426 |
|
| Company Name: |
Lynnchem
|
| Tel: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
| Company Name: |
Novachemistry
|
| Tel: |
44-20819178-90 02081917890 |
| Website: |
https://www.novachemistry.com/ |
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|